<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Int Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Int Med</journal-id><journal-id journal-id-type="publisher-id">jtim</journal-id><journal-id journal-id-type="doi">jtim</journal-id><journal-title-group><journal-title>Journal of Translational Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">2450-131X</issn><issn pub-type="epub">2224-4018</issn><publisher><publisher-name>De Gruyter</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10732574</article-id><article-id pub-id-type="publisher-id">jtim-2023-0094</article-id><article-id pub-id-type="doi">10.2478/jtim-2023-0094</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Mucus hypersecretion in chronic obstructive pulmonary disease: From molecular mechanisms to treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ruonan</given-names></name><xref rid="j_jtim-2023-0094_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xiaojie</given-names></name><xref rid="j_jtim-2023-0094_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Gounni</surname><given-names>Abdelilah Soussi</given-names></name><xref rid="j_jtim-2023-0094_aff_003" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xie</surname><given-names>Jungang</given-names><prefix>Prof.</prefix></name><email xlink:href="mailto:xiejjgg@hotmail.com">xiejjgg@hotmail.com</email><xref rid="j_jtim-2023-0094_aff_001" ref-type="aff"/></contrib><aff id="j_jtim-2023-0094_aff_001"><institution>Department of Respiratory and Critical Care Medicine, National Clinical Research Center of Respiratory Disease, Key Laboratory of Pulmonary Diseases of Health Ministry, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>, <city>Wuhan</city>
<postal-code>430030</postal-code>, <addr-line>Hubei Province</addr-line>, <country country="CN">China</country></aff><aff id="j_jtim-2023-0094_aff_002"><institution>Department of Respiratory and Critical Care Medicine, Wuhan NO. 1 Hospital, Wuhan Hospital of traditional Chinese and Western Medicine</institution>, <city>Wuhan</city>
<postal-code>430022</postal-code>, <addr-line>Hubei Province</addr-line>, <country country="CN">China</country></aff><aff id="j_jtim-2023-0094_aff_003"><institution>Department of Immunology, Faculty of Medicine, University of Manitoba</institution>, <city>Manitoba</city>
<postal-code>R3E 0W3</postal-code>, <country country="CA">Canada</country></aff></contrib-group><author-notes><corresp>Prof. Jungang Xie, Department of Respiratory and Critical Care Medicine, National Clinical Research Center of Respiratory Disease, Key Laboratory of Pulmonary Diseases of Health Ministry, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>12</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2023</year></pub-date><volume>11</volume><issue>4</issue><fpage>312</fpage><lpage>315</lpage><permissions><copyright-statement>&#x000a9; 2023 Ruonan Yang, Xiaojie Wu, Abdelilah Soussi Gounni, Jungang Xie, published by De Gruyter on behalf of Scholar Media Publishing</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Ruonan Yang, Xiaojie Wu, Abdelilah Soussi Gounni, Jungang Xie, published by De Gruyter on behalf of Scholar Media Publishing</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License.</license-p></license></permissions><funding-group><funding-statement>This study was supported by the National Natural Science Foundation of China (No., 82170049, 81973986), Health Research Fund of Wuhan (No. WX21Q07) and Leading talents of public health in Hubei Province (2022SCZ047).</funding-statement></funding-group><counts><page-count count="4"/></counts></article-meta></front><body><sec id="j_jtim-2023-0094_s_001"><title>Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is among the leading causes of mortality and morbidity worldwide, which has caused tremendous burden on society.<sup>[<xref rid="j_jtim-2023-0094_ref_001" ref-type="bibr">1</xref>,<xref rid="j_jtim-2023-0094_ref_002" ref-type="bibr">2</xref>]</sup> Mucus hypersecretion is recognized as one of the main pathophysiological changes and is associated with lung function decline, exacerbations, hospitalization and mortality in patients with COPD.<sup>[<xref rid="j_jtim-2023-0094_ref_003" ref-type="bibr">3</xref>]</sup> Exposure to cigarette smoke or other irritants promote submucosal gland hypertrophy and goblet cell metaplasia to overproduce mucus through the activation of a variety of signaling pathways. In turn, mucus accumulated in airways worsens the symptoms of airway obstruction and hypoxemia.<sup>[<xref rid="j_jtim-2023-0094_ref_004" ref-type="bibr">4</xref>]</sup> With the function of blocking specific signaling pathway, it has been identified that drugs targeting mucus hypersecretion can not only alleviate clinical symptoms but also reduce the respiratory inflammatory response in COPD.<sup>[<xref rid="j_jtim-2023-0094_ref_005" ref-type="bibr">5</xref>]</sup></p><p>Thus, research for a better understanding about molecular mechanisms of mucus hypersecretion has become a hotspot for the treatment of COPD.</p></sec><sec id="j_jtim-2023-0094_s_002"><title>Risk factors of airway mucus hypersecretion</title><p>The most common exogenous factor that stimulates mucus hypersecretion is cigarette smoke.<sup>[<xref rid="j_jtim-2023-0094_ref_006" ref-type="bibr">6</xref>]</sup> Previous studies have shown that cigarette smoke extract (CSE) can increase the expression of mucin-5 subtype AC(MUC5AC) in a concentration-dependent manner.<sup>[<xref rid="j_jtim-2023-0094_ref_007" ref-type="bibr">7</xref>]</sup> Another common risk factor is particulate matter 2.5 (PM2.5), which can be deposited in the small airways and induce MUC5AC expression caused by oxidative stress.<sup>[<xref rid="j_jtim-2023-0094_ref_008" ref-type="bibr">8</xref>,<xref rid="j_jtim-2023-0094_ref_009" ref-type="bibr">9</xref>]</sup></p><p>Most of endogenous factors that induce mucus hypersecretion are inflammatory mediators, including neutrophil elastase (NE),<sup>[<xref rid="j_jtim-2023-0094_ref_010" ref-type="bibr">10</xref>]</sup> interleukin-13 (IL-13),<sup>[<xref rid="j_jtim-2023-0094_ref_011" ref-type="bibr">11</xref>]</sup> interleukin- 1&#x003b2; (IL-1&#x003b2;),<sup>[<xref rid="j_jtim-2023-0094_ref_012" ref-type="bibr">12</xref>]</sup>interleukin-4 (IL-4),<sup>[<xref rid="j_jtim-2023-0094_ref_013" ref-type="bibr">13</xref>]</sup> lipopolysaccharide(LPS),<sup>[<xref rid="j_jtim-2023-0094_ref_014" ref-type="bibr">14</xref>]</sup> matrix metalloproteinase-9 (MMP-9),<sup>[<xref rid="j_jtim-2023-0094_ref_015" ref-type="bibr">15</xref>]</sup>
<italic toggle="yes">etc</italic>. To date, NE is the most potent secretagogue.<sup>[<xref rid="j_jtim-2023-0094_ref_016" ref-type="bibr">16</xref>]</sup> NE can cleave pro-transforming growth factor (TGF)-&#x003b1; to release mature TGF-&#x003b1;, which can activate epidermal growth factor receptor (EGFR) signaling in a ligand-dependent manner. In addition, NE is locally released to induce goblet cell degranulation when neutrophils and goblet cells are in close contact.<sup>[<xref rid="j_jtim-2023-0094_ref_017" ref-type="bibr">17</xref>]</sup></p></sec><sec id="j_jtim-2023-0094_s_003"><title>Molecular mechanisms of airway mucus hypersecretion</title><sec id="j_jtim-2023-0094_s_003_s_001"><title>Signaling pathways leading to mucus overproduction</title><p>EGFR signaling pathway: EGFR is activated by exogenous reactive oxygen species (ROS) induced by cigarette smoke and endogenous ROS generated by neutrophils. The downstream of EGFR can activate the nuclear transcription factors like nuclear factor kB (NF-kB) to trigger the transcription of MUC gene.<sup>[<xref rid="j_jtim-2023-0094_ref_018" ref-type="bibr">18</xref>]</sup> Moreover, EGFR can phosphorylate signal transducer and activator of transcription 6 (STAT6), resulting in the down-regulation of forkhead box A2 (FOXA2) expression, thereby promoting the proliferation of goblet cells and the secretion of mucus.<sup>[<xref rid="j_jtim-2023-0094_ref_019" ref-type="bibr">19</xref>]</sup></p><p>NF-kB signaling pathway: Both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>, tumor necrosis factor (TNF)-&#x003b1;-mediated mucin production is dependent on I&#x0041a;B kinase (IKK) and NF-kB. NF-kB can regulate a variety of genes, including the MUC gene. Sequence analysis of the MUC2 and MUC5AC promoter clones revealed the presence of NF-kB response elements.<sup>[<xref rid="j_jtim-2023-0094_ref_020" ref-type="bibr">20</xref>]</sup> A study in mouse models of COPD has demonstrated that NF-kB is essential for mucus production.<sup>[<xref rid="j_jtim-2023-0094_ref_021" ref-type="bibr">21</xref>]</sup></p><p>p38 mitogen-activated protein kinase (MAPK) signaling pathway: p38 kinase, a member of the MAPK family, is a highly conserved protein kinase that can be activated by many inflammatory signals. Hemophilus influenzae is a common pathogen of COPD, and studies have found that Hemophilus influenzae can upregulate MUC gene transcription through the activation of TLR2-MyD88-dependent p38 MAPK pathway.<sup>[<xref rid="j_jtim-2023-0094_ref_022" ref-type="bibr">22</xref>]</sup></p></sec><sec id="j_jtim-2023-0094_s_003_s_002"><title>Signaling pathways leading to mucus secretion and clearance dysfunction</title><p>Myristoylated alanine-rich C kinase substrate (MARCKS) protein signaling pathway: MARCKS is a key regulatory molecule that mediates the release of mucin granules from human bronchial epithelial (HBE) cells.<sup>[<xref rid="j_jtim-2023-0094_ref_023" ref-type="bibr">23</xref>]</sup> Phosphorylation of MARCKS by protein kinase C(PKC) leads to its translocation to the cytoplasm, followed by dephosphorylation of MARCKS by protein kinase G (PKG). Dephosphorylated MARCKS can bind to the membrane of mucin granules, then MARCKS promotes the transport of mucin granules to the membrane for release.<sup>[<xref rid="j_jtim-2023-0094_ref_024" ref-type="bibr">24</xref>]</sup></p><p>Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein signaling pathway: SNARE proteins can initiate vesicle fusion, regulate intracellular membrane fusion events, and participate in the fusion of mucin particles and cell membranes. Through interacting with Ca<sup>2+</sup> sensor and other factors, SNARE proteins mediate Ca<sup>2+</sup>-triggered mucin exocytosis.<sup>[<xref rid="j_jtim-2023-0094_ref_025" ref-type="bibr">25</xref>]</sup> Studies have shown that the most abundant SNARE protein in the airway epithelium is mainly vesicle-associated membrane protein 8 (VAMP8).<sup>[<xref rid="j_jtim-2023-0094_ref_026" ref-type="bibr">26</xref>]</sup></p><p>Epithelial sodium channel (ENaC) signaling pathway: Airway surface hydration is mainly controlled by ENaC and cystic fibrosis transmembrane regulator (CFTR) pathways. Studies have shown that cigarette smoke-induced ROS can disrupt the function and activity of ENaC, thereby disrupting mucin hydration and reducing mucus expulsion.<sup>[<xref rid="j_jtim-2023-0094_ref_027" ref-type="bibr">27</xref>]</sup></p><p>Ciliophagy signaling pathway: Normal ciliary structure and function help to transport the mucus from the airway to the larynx. A study has demonstrated that histone deacetylase 6 (HDAC6) and other regulators of the autophagic pathway can lead to cilia shortening and abnormal function, resulting in impaired mucociliary clearance during CS exposure.<sup>[<xref rid="j_jtim-2023-0094_ref_028" ref-type="bibr">28</xref>]</sup></p></sec></sec><sec id="j_jtim-2023-0094_s_004"><title>Treatment of airway mucus hypersecretion</title><p>For the above-mentioned risk factors and signaling pathways of airway mucus hypersecretion, the current treatment principles include eliminating exogenous risk factors, inhibiting mucus synthesis and secretion, promoting mucus clearance and other physical expectoration therapy.<sup>[<xref rid="j_jtim-2023-0094_ref_029" ref-type="bibr">29</xref>]</sup> It has also been summarized in the <xref rid="j_jtim-2023-0094_tab_001" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="j_jtim-2023-0094_tab_001"><label>Table 1</label><caption><p>Targets and relative inhibitors for the treatment of mucus hypersecretion in COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Target</th><th align="left" rowspan="1" colspan="1">Inhibitor(s)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Smoking, PM2.5</td><td align="left" rowspan="1" colspan="1">Smoking cessation, improvement of air quality</td></tr><tr><td align="left" rowspan="1" colspan="1">Mucus synthesis</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NE</td><td align="left" rowspan="1" colspan="1">NE inhibitors, batimastat, suramin</td></tr><tr><td align="left" rowspan="1" colspan="1">EGFR</td><td align="left" rowspan="1" colspan="1">EGFR tyrosine kinase inhibitors: AG1478, BIBX1522, ZD1839</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">p38 MAPK inhibitors: SB-202190</td></tr><tr><td align="left" rowspan="1" colspan="1">p38 MAPK NF-kB</td><td align="left" rowspan="1" colspan="1">Macrolide antibiotics: erythromycin, flurythromycin</td></tr><tr><td align="left" rowspan="1" colspan="1">Mucus secretion</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MARCKS</td><td align="left" rowspan="1" colspan="1">MARCKS inhibitors: MARCKS-specific antisense oligonucleotides</td></tr><tr><td align="left" rowspan="1" colspan="1">SNARE</td><td align="left" rowspan="1" colspan="1">SNARE protein inhibitors: EGF-LHN-C</td></tr><tr><td align="left" rowspan="1" colspan="1">Mucus clearance</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cholinergic pathway Mucus viscosity</td><td align="left" rowspan="1" colspan="1">Expectorants: Guaifenesin, hypertonic saline</td></tr><tr><td align="left" rowspan="1" colspan="1">P2Y2</td><td align="left" rowspan="1" colspan="1">Mucolytics: N-Acetyl Cysteine</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P2Y2 receptor agonists</td></tr></tbody></table><table-wrap-foot><fn><p>COPE: Chronic obstructive pulmonary disease; NE: neutrophil elastase; EGFR: epidermal growth factor receptor; MAPK: mitogen-activated protein kinase; MARCKS: myristoylated alanine-rich C kinase substrate; SNARE: soluble N-ethylmaleimide-sensitive factor attachment protein receptor; NF-kB: nuclear factor kappa B.</p></fn></table-wrap-foot></table-wrap><sec id="j_jtim-2023-0094_s_004_s_001"><title>Elimination of exogenous risk factors</title><p>As described above, smoking and air pollution are important risk factors for COPD. Therefore, smoking cessation and improvement of air quality should be the primary measures to prevent and treat mucus hypersecretion in chronic airway inflammatory diseases.<sup>[<xref rid="j_jtim-2023-0094_ref_030" ref-type="bibr">30</xref>]</sup></p></sec><sec id="j_jtim-2023-0094_s_004_s_002"><title>Drugs that inhibit mucus synthesis</title><p>EGFR tyrosine kinase inhibitors: Cigarette smoke, PM2.5 and oxidative stress can all stimulate EGFR activation, resulting in increased mucin secretion. It can be seen that the EGFR signaling pathway plays a central regulatory role in mucus hypersecretion. Studies have shown that pretreatment with the selective EGFR tyrosine kinase inhibitor BIBX1522 can effectively prevent the secretion of MUC5AC in asthma models and in a rat model of TNF-&#x003b1;-induced mucus hypersecretion.<sup>[<xref rid="j_jtim-2023-0094_ref_031" ref-type="bibr">31</xref>]</sup></p><p>Macrolide antibiotics: Studies have shown that macrolide antibiotics can significantly reduce LPS-induced expression of MUC5AC in rat bronchi and reduce neutrophil counts as well as mucin levels in bronchoalveolar lavage fluid, which may be caused by the inactivation of NF-kB.<sup>[<xref rid="j_jtim-2023-0094_ref_032" ref-type="bibr">32</xref>]</sup> Another study has shown that macrolide antibiotics can quickly accumulate in neutrophils and macrophages, thus inhibiting the secretion of NE and mucus secretion.<sup>[<xref rid="j_jtim-2023-0094_ref_033" ref-type="bibr">33</xref>]</sup></p><p>NE inhibitors: Studies have shown that the NE inhibitor ONO-5046 can reverse ozone-induced mucus hypersecretion and neutrophil aggregation in guinea pig models.<sup>[<xref rid="j_jtim-2023-0094_ref_034" ref-type="bibr">34</xref>]</sup> The selective NE inhibitor ICI2000355 has also been shown to reverse mucus hypersecretion induced by ovalbumin sensitization in guinea pig models.<sup>[<xref rid="j_jtim-2023-0094_ref_035" ref-type="bibr">35</xref>]</sup></p><p>p38 MAPK inhibitors: Administration of the p38 MAPK inhibitor (SB-202190) significantly improved IL-13-induced goblet cell hyperplasia <italic toggle="yes">in vitro</italic>.<sup>[<xref rid="j_jtim-2023-0094_ref_036" ref-type="bibr">36</xref>]</sup></p></sec><sec id="j_jtim-2023-0094_s_004_s_003"><title>Drugs that inhibit mucus secretion</title><p>MARCKS inhibitors: As previously mentioned, MARCKS mediates the intracellular movement and exocytosis of mucin particles.<sup>[<xref rid="j_jtim-2023-0094_ref_024" ref-type="bibr">24</xref>]</sup> Studies have shown that MARCKS-specific antisense oligonucleotides can downregulate MARCKS levels in HBE cells and significantly attenuate PKC/PKG activation-induced mucin secretion.<sup>[<xref rid="j_jtim-2023-0094_ref_037" ref-type="bibr">37</xref>]</sup></p><p>SNARE protein inhibitors: SNARE protein inhibitor (EGF-LHN-C) inhibits mucin secretion by inhibiting the fusion of mucin granules with the cell membrane.<sup>[<xref rid="j_jtim-2023-0094_ref_038" ref-type="bibr">38</xref>]</sup></p></sec><sec id="j_jtim-2023-0094_s_004_s_004"><title>Drugs that promote mucus clearance</title><p>Expectorants: Expectorants can stimulate the cholinergic pathway and increase the secretion of serous fluid from the bronchial submucosal glands to reduce mucus viscosity, resulting in promotion of mucus clearance.<sup>[<xref rid="j_jtim-2023-0094_ref_039" ref-type="bibr">39</xref>]</sup></p><p>Mucolytics: With the characteristics of reducing mucus viscosity, mucolytics are the most widely used drugs for the treatment of mucus hypersecretion. For example, N-Acetyl Cysteine (NAC) can break disulphide bonds linking mucin polymers to reduce the viscosity of mucus.<sup>[<xref rid="j_jtim-2023-0094_ref_040" ref-type="bibr">40</xref>]</sup></p><p>Purinergic receptor P2Y, G-protein coupled, 2 (P2Y2) receptor agonists: Studies have shown that the efficiency of P2Y2 receptor agonists to increase airway mucus clearance is significantly greater than that of hypertonic saline solution, which may be related to the increase of water secretion and ciliary beating frequency by P2Y2 receptor agonists.<sup>[<xref rid="j_jtim-2023-0094_ref_041" ref-type="bibr">41</xref>]</sup></p><p>In addition to the above drug treatment, the symptoms of patients can be alleviated to a certain extent through autogenic drainage,<sup>[<xref rid="j_jtim-2023-0094_ref_042" ref-type="bibr">42</xref>]</sup> high-frequency chest wall oscillation (HFCWO)<sup>[<xref rid="j_jtim-2023-0094_ref_043" ref-type="bibr">43</xref>]</sup> and bronchoscopic treatment.<sup>[<xref rid="j_jtim-2023-0094_ref_044" ref-type="bibr">44</xref>]</sup></p></sec></sec><sec id="j_jtim-2023-0094_s_005"><title>Summary</title><p>So far, some progress has been made in the molecular mechanisms and drug treatment of mucus hypersecretion in COPD. A variety of drugs have been found to have certain therapeutic effects on mucus hypersecretion. However, most of the above drugs are still in the experimental research stage and there is still a long way to go before they can be used in clinical treatment. Further investigation is urgently needed to develop understanding and therapies for airway mucus hypersecretion in COPD.</p></sec></body><back><fn-group><fn fn-type="con" id="j_jtim-2023-0094_fn_102"><p>
<bold>Conflicts of Interest</bold>
</p><p>The authors declare that there is no conflict of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="j_jtim-2023-0094_ref_001"><label>1</label><element-citation publication-type="journal"><article-title>Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015</article-title><source>Lancet Respir Med</source><year>2017</year><volume>5</volume><fpage>691</fpage><comment>&#x02013;</comment><lpage>706</lpage><pub-id pub-id-type="pmid">28822787</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_002"><label>2</label><element-citation publication-type="journal"><name><surname>Labaki</surname><given-names>WW</given-names></name><name><surname>Rosenberg</surname><given-names>SR</given-names></name><article-title>Chronic Obstructive Pulmonary Disease</article-title><source>Ann Intern Med</source><year>2020</year><volume>173</volume><fpage>ITC17</fpage><comment>&#x02013;</comment><lpage>32</lpage><pub-id pub-id-type="pmid">32745458</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_003"><label>3</label><element-citation publication-type="journal"><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Frija-Masson</surname><given-names>J</given-names></name><name><surname>Burgel</surname><given-names>P-R</given-names></name><article-title>Targeting mucus hypersecretion: new therapeutic opportunities for COPD?</article-title><source>Drugs</source><year>2014</year><volume>74</volume><fpage>1073</fpage><comment>&#x02013;</comment><lpage>89</lpage><pub-id pub-id-type="pmid">24890395</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_004"><label>4</label><element-citation publication-type="journal"><name><surname>Dunican</surname><given-names>EM</given-names></name><name><surname>Elicker</surname><given-names>BM</given-names></name><name><surname>Henry</surname><given-names>T</given-names></name><name><surname>Gierada</surname><given-names>DS</given-names></name><name><surname>Schiebler</surname><given-names>ML</given-names></name><name><surname>Anderson</surname><given-names>W</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers</article-title><source>Am J Respir Crit Care Med</source><year>2021</year><volume>203</volume><fpage>957</fpage><comment>&#x02013;</comment><lpage>68</lpage><pub-id pub-id-type="pmid">33180550</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_005"><label>5</label><element-citation publication-type="journal"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Hogg</surname><given-names>JC</given-names></name><article-title>Convergence of the epidemiology and pathology of COPD</article-title><source>Thorax</source><year>2006</year><volume>61</volume><fpage>86</fpage><comment>&#x02013;</comment><lpage>8</lpage><pub-id pub-id-type="pmid">16227325</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_006"><label>6</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Mitoquinone ameliorates cigarette smoke-induced airway inflammation and mucus hypersecretion in mice</article-title><source>Int Immunopharmacol</source><year>2021</year><volume>90</volume><fpage>107149</fpage><pub-id pub-id-type="pmid">33191175</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_007"><label>7</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Ip</surname><given-names>MSM</given-names></name><name><surname>Zhang</surname><given-names>KY</given-names></name><name><surname>Mak</surname><given-names>JCW</given-names></name><article-title>Amelioration of Cigarette Smoke-Induced Mucus Hypersecretion and Viscosity by Polysaccharides In Vitro and In Vivo</article-title><source>Oxid Med Cell Longev</source><year>2020</year><volume>2020</volume><fpage>8217642</fpage><pub-id pub-id-type="pmid">33144914</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_008"><label>8</label><element-citation publication-type="journal"><name><surname>Val</surname><given-names>S</given-names></name><name><surname>Belade</surname><given-names>E</given-names></name><name><surname>George</surname><given-names>I</given-names></name><name><surname>Boczkowski</surname><given-names>J</given-names></name><name><surname>Baeza-Squiban</surname><given-names>A</given-names></name><article-title>Fine PM induce airway MUC5AC expression through the autocrine effect of amphiregulin</article-title><source>Arch Toxicol</source><year>2012</year><volume>86</volume><fpage>1851</fpage><comment>&#x02013;</comment><lpage>9</lpage><pub-id pub-id-type="pmid">22820758</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_009"><label>9</label><element-citation publication-type="journal"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xiong</surname><given-names>A</given-names></name><name><surname>Ran</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>PM2.5 aggravates NQO1-induced mucus hyper-secretion through release of neutrophil extracellular traps in an asthma model</article-title><source>Ecotoxicol Environ Saf</source><year>2021</year><volume>218</volume><fpage>112272</fpage><pub-id pub-id-type="pmid">33962274</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_010"><label>10</label><element-citation publication-type="journal"><name><surname>Gehrig</surname><given-names>S</given-names></name><name><surname>Duerr</surname><given-names>J</given-names></name><name><surname>Weitnauer</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>CJ</given-names></name><name><surname>Graeber</surname><given-names>SY</given-names></name><name><surname>Schatterny</surname><given-names>J</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease</article-title><source>Am J Respir Crit Care Med</source><year>2014</year><volume>189</volume><fpage>1082</fpage><comment>&#x02013;</comment><lpage>92</lpage><pub-id pub-id-type="pmid">24678594</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_011"><label>11</label><element-citation publication-type="journal"><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Johansson</surname><given-names>K</given-names></name><name><surname>Joo</surname><given-names>A</given-names></name><name><surname>Bonser</surname><given-names>LR</given-names></name><name><surname>Koh</surname><given-names>KD</given-names></name><name><surname>Le Tonqueze</surname><given-names>O</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Epithelial miR- 141 regulates IL-13-induced airway mucus production</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><fpage>139019</fpage><pub-id pub-id-type="pmid">33682796</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_012"><label>12</label><element-citation publication-type="journal"><name><surname>Faiz</surname><given-names>A</given-names></name><name><surname>Weckmann</surname><given-names>M</given-names></name><name><surname>Tasena</surname><given-names>H</given-names></name><name><surname>Vermeulen</surname><given-names>CJ</given-names></name><name><surname>Van</surname><given-names>den Berge M</given-names></name><name><surname>Ten</surname><given-names>Hacken NHT</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Profiling of healthy and asthmatic airway smooth muscle cells following interleukin-1&#x003b2; treatment: a novel role for CCL20 in chronic mucus hypersecretion</article-title><source>Eur Respir J</source><year>2018</year><volume>52</volume><fpage>1800310</fpage><pub-id pub-id-type="pmid">29946002</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_013"><label>13</label><element-citation publication-type="journal"><name><surname>Hammad</surname><given-names>H</given-names></name><name><surname>Lambrecht</surname><given-names>BN</given-names></name><article-title>The basic immunology of asthma</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>1469</fpage><comment>&#x02013;</comment><lpage>85</lpage><pub-id pub-id-type="pmid">33711259</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_014"><label>14</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name><article-title>Casticin alleviates lipopolysaccharide-induced inflammatory responses and expression of mucus and extracellular matrix in human airway epithelial cells through Nrf2/Keap1 and NF-&#x003ba;B pathways</article-title><source>Phytother Res: PTR</source><year>2018</year><volume>32</volume><fpage>1346</fpage><comment>&#x02013;</comment><lpage>53</lpage><pub-id pub-id-type="pmid">29508465</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_015"><label>15</label><element-citation publication-type="journal"><name><surname>Deshmukh</surname><given-names>HS</given-names></name><name><surname>Case</surname><given-names>LM</given-names></name><name><surname>Wesselkamper</surname><given-names>SC</given-names></name><name><surname>Borchers</surname><given-names>MT</given-names></name><name><surname>Martin</surname><given-names>LD</given-names></name><name><surname>Shertzer</surname><given-names>HG</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Metalloproteinases mediate mucin 5AC expression by epidermal growth factor receptor activation</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>171</volume><fpage>305</fpage><comment>&#x02013;</comment><lpage>14</lpage><pub-id pub-id-type="pmid">15531749</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_016"><label>16</label><element-citation publication-type="journal"><name><surname>Sommerhoff</surname><given-names>CP</given-names></name><name><surname>Nadel</surname><given-names>JA</given-names></name><name><surname>Basbaum</surname><given-names>CB</given-names></name><name><surname>Caughey</surname><given-names>GH</given-names></name><article-title>Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells</article-title><source>J Clin Invest</source><year>1990</year><volume>85</volume><fpage>682</fpage><comment>&#x02013;</comment><lpage>9</lpage><pub-id pub-id-type="pmid">2107207</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_017"><label>17</label><element-citation publication-type="journal"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Nadel</surname><given-names>JA</given-names></name><article-title>Role of neutrophils in mucus hypersecretion in COPD and implications for therapy</article-title><source>Treat Respir Med</source><year>2004</year><volume>3</volume><fpage>147</fpage><comment>&#x02013;</comment><lpage>59</lpage><pub-id pub-id-type="pmid">15219174</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_018"><label>18</label><element-citation publication-type="journal"><name><surname>Rubin</surname><given-names>BK</given-names></name><name><surname>Priftis</surname><given-names>KN</given-names></name><name><surname>Schmidt</surname><given-names>HJ</given-names></name><name><surname>Henke</surname><given-names>MO</given-names></name><article-title>Secretory hyperresponsiveness and pulmonary mucus hypersecretion</article-title><source>Chest</source><year>2014</year><volume>146</volume><fpage>496</fpage><comment>&#x02013;</comment><lpage>507</lpage><pub-id pub-id-type="pmid">25091755</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_019"><label>19</label><element-citation publication-type="journal"><name><surname>Oh</surname><given-names>S-Y</given-names></name><name><surname>Kim</surname><given-names>Y-H</given-names></name><name><surname>Kang</surname><given-names>M-K</given-names></name><name><surname>Lee</surname><given-names>E-J</given-names></name><name><surname>Kim</surname><given-names>D-Y</given-names></name><name><surname>Oh</surname><given-names>H</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Aesculetin Inhibits Airway Thickening and Mucus Overproduction Induced by Urban Particulate Matter through Blocking Inflammation and Oxidative Stress Involving TLR4 and EGFR</article-title><source>Antioxidants</source><comment>(Basel)</comment><year>2021</year><volume>10</volume><fpage>494</fpage><pub-id pub-id-type="pmid">33809902</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_020"><label>20</label><element-citation publication-type="journal"><name><surname>Lai</surname><given-names>H</given-names></name><name><surname>Rogers</surname><given-names>DF</given-names></name><article-title>New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways</article-title><source>J Aerosol Med Pulm Drug Deliv</source><year>2010</year><volume>23</volume><fpage>219</fpage><comment>&#x02013;</comment><lpage>31</lpage><pub-id pub-id-type="pmid">20695774</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_021"><label>21</label><element-citation publication-type="journal"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>MicroRNA-218 acts by repressing TNFR1-mediated activation of NF-&#x003ba;B, which is involved in MUC5AC hyper-production and inflammation in smoking-induced bronchiolitis of COPD</article-title><source>Toxicol Lett</source><year>2017</year><volume>280</volume><fpage>171</fpage><comment>&#x02013;</comment><lpage>80</lpage><pub-id pub-id-type="pmid">28864214</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_022"><label>22</label><element-citation publication-type="journal"><name><surname>Gaffey</surname><given-names>K</given-names></name><name><surname>Reynolds</surname><given-names>S</given-names></name><name><surname>Plumb</surname><given-names>J</given-names></name><name><surname>Kaur</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><article-title>Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs</article-title><source>Eur Respir J</source><year>2013</year><volume>42</volume><fpage>28</fpage><comment>&#x02013;</comment><lpage>41</lpage><pub-id pub-id-type="pmid">23060629</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_023"><label>23</label><element-citation publication-type="journal"><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Crews</surname><given-names>AL</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>X-R</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>MARCKS and HSP70 interactions regulate mucin secretion by human airway epithelial cells in vitro</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2013</year><volume>304</volume><fpage>L511</fpage><comment>&#x02013;</comment><lpage>L8</lpage><pub-id pub-id-type="pmid">23377348</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_024"><label>24</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>LD</given-names></name><name><surname>Spizz</surname><given-names>G</given-names></name><name><surname>Adler</surname><given-names>KB</given-names></name><article-title>MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>40982</fpage><comment>&#x02013;</comment><lpage>90</lpage><pub-id pub-id-type="pmid">11533058</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_025"><label>25</label><element-citation publication-type="journal"><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Fois</surname><given-names>G</given-names></name><name><surname>Flores</surname><given-names>JR</given-names></name><name><surname>Tuvim</surname><given-names>MJ</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Inhibition of calcium-triggered secretion by hydrocarbon-stapled peptides</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>949</fpage><comment>&#x02013;</comment><lpage>56</lpage><pub-id pub-id-type="pmid">35322233</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_026"><label>26</label><element-citation publication-type="journal"><name><surname>Jones</surname><given-names>LC</given-names></name><name><surname>Moussa</surname><given-names>L</given-names></name><name><surname>Fulcher</surname><given-names>ML</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Hudson</surname><given-names>EJ</given-names></name><name><surname>O&#x02019;Neal</surname><given-names>WK</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>VAMP8 is a vesicle SNARE that regulates mucin secretion in airway goblet cells</article-title><source>J Physiol</source><year>2012</year><volume>590</volume><fpage>545</fpage><comment>&#x02013;</comment><lpage>62</lpage><pub-id pub-id-type="pmid">22144578</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_027"><label>27</label><element-citation publication-type="journal"><name><surname>&#x000c5;strand</surname><given-names>ABM</given-names></name><name><surname>Hemmerling</surname><given-names>M</given-names></name><name><surname>Root</surname><given-names>J</given-names></name><name><surname>Wingren</surname><given-names>C</given-names></name><name><surname>Pesic</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>E</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2015</year><volume>308</volume><fpage>L22</fpage><comment>&#x02013;</comment><lpage>L32</lpage><pub-id pub-id-type="pmid">25361567</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_028"><label>28</label><element-citation publication-type="journal"><name><surname>Cloonan</surname><given-names>SM</given-names></name><name><surname>Lam</surname><given-names>HC</given-names></name><name><surname>Ryter</surname><given-names>SW</given-names></name><name><surname>Choi</surname><given-names>AM.</given-names></name><article-title>&#x0201c;Ciliophagy&#x0201d;: The consumption of cilia components by autophagy</article-title><source>Autophagy</source><year>2014</year><volume>10</volume><fpage>532</fpage><comment>&#x02013;</comment><lpage>4</lpage><pub-id pub-id-type="pmid">24401596</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_029"><label>29</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><article-title>Recent Advances in the Development of Novel Drug Candidates for Regulating the Secretion of Pulmonary Mucus</article-title><source>Biomol Ther (Seoul)</source><year>2020</year><volume>28</volume><fpage>293</fpage><comment>&#x02013;</comment><lpage>301</lpage><pub-id pub-id-type="pmid">32133827</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_030"><label>30</label><element-citation publication-type="journal"><name><surname>Willemse</surname><given-names>BWM</given-names></name><name><surname>ten Hacken</surname><given-names>NHT</given-names></name><name><surname>Rutgers</surname><given-names>B</given-names></name><name><surname>Lesman-Leegte</surname><given-names>IGAT</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><article-title>Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD</article-title><source>Eur Respir J</source><year>2004</year><volume>24</volume><fpage>391</fpage><comment>&#x02013;</comment><lpage>6</lpage><pub-id pub-id-type="pmid">15358697</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_031"><label>31</label><element-citation publication-type="journal"><name><surname>Takeyama</surname><given-names>K</given-names></name><name><surname>Dabbagh</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>HM</given-names></name><name><surname>Agust&#x000ed;</surname><given-names>C</given-names></name><name><surname>Lausier</surname><given-names>JA</given-names></name><name><surname>Ueki</surname><given-names>IF</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Epidermal growth factor system regulates mucin production in airways</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>3081</fpage><comment>&#x02013;</comment><lpage>6</lpage><pub-id pub-id-type="pmid">10077640</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_032"><label>32</label><element-citation publication-type="journal"><name><surname>Ou</surname><given-names>X-M</given-names></name><name><surname>Feng</surname><given-names>Y-L</given-names></name><name><surname>Wen</surname><given-names>F-Q</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>Z-P</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Macrolides attenuate mucus hypersecretion in rat airways through inactivation of NF-kappaB</article-title><source>Respirology</source><year>2008</year><volume>13</volume><fpage>63</fpage><comment>&#x02013;</comment><lpage>72</lpage><pub-id pub-id-type="pmid">18197913</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_033"><label>33</label><element-citation publication-type="journal"><name><surname>Spagnolo</surname><given-names>P</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name><article-title>Long-term macrolide treatment for chronic respiratory disease</article-title><source>Eur Respir J</source><year>2013</year><volume>42</volume><fpage>239</fpage><comment>&#x02013;</comment><lpage>51</lpage><pub-id pub-id-type="pmid">23180583</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_034"><label>34</label><element-citation publication-type="journal"><name><surname>Nogami</surname><given-names>H</given-names></name><name><surname>Aizawa</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Koto</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>H</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Neutrophil elastase inhibitor, ONO-5046 suppresses ozone-induced airway mucus hypersecretion in guinea pigs</article-title><source>Eur J Pharmacol</source><year>2000</year><volume>390</volume><fpage>197</fpage><comment>&#x02013;</comment><lpage>202</lpage><pub-id pub-id-type="pmid">10708724</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_035"><label>35</label><element-citation publication-type="journal"><name><surname>Voynow</surname><given-names>JA</given-names></name><name><surname>Young</surname><given-names>LR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Horger</surname><given-names>T</given-names></name><name><surname>Rose</surname><given-names>MC</given-names></name><name><surname>Fischer</surname><given-names>BM</given-names></name><article-title>Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells</article-title><source>Am J Physiol</source><year>1999</year><volume>276</volume><fpage>L835</fpage><comment>&#x02013;</comment><lpage>L43</lpage><pub-id pub-id-type="pmid">10330040</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_036"><label>36</label><element-citation publication-type="journal"><name><surname>Atherton</surname><given-names>HC</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Danahay</surname><given-names>H</given-names></name><article-title>IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2003</year><volume>285</volume><fpage>L730</fpage><comment>&#x02013;</comment><lpage>L9</lpage><pub-id pub-id-type="pmid">12794003</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_037"><label>37</label><element-citation publication-type="journal"><name><surname>Poole</surname><given-names>PJ</given-names></name><name><surname>Black</surname><given-names>PN</given-names></name><article-title>Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents</article-title><source>Am J Respir Med</source><year>2003</year><volume>2</volume><fpage>367</fpage><comment>&#x02013;</comment><lpage>70</lpage><pub-id pub-id-type="pmid">14719989</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_038"><label>38</label><element-citation publication-type="journal"><name><surname>Rogers</surname><given-names>DF</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><article-title>Treatment of airway mucus hypersecretion</article-title><source>Ann Med</source><year>2006</year><volume>38</volume><fpage>116</fpage><comment>&#x02013;</comment><lpage>25</lpage><pub-id pub-id-type="pmid">16581697</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_039"><label>39</label><element-citation publication-type="journal"><name><surname>Ohar</surname><given-names>JA</given-names></name><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Spangenthal</surname><given-names>S</given-names></name><article-title>The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review</article-title><source>Chronic Obstr Pulm Dis</source><year>2019</year><volume>6</volume><fpage>341</fpage><comment>&#x02013;</comment><lpage>349</lpage><pub-id pub-id-type="pmid">31647856</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_040"><label>40</label><element-citation publication-type="journal"><name><surname>Lin</surname><given-names>VY</given-names></name><name><surname>Kaza</surname><given-names>N</given-names></name><name><surname>Birket</surname><given-names>SE</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Edwards</surname><given-names>LJ</given-names></name><name><surname>LaFontaine</surname><given-names>J</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Excess mucus viscosity and airway dehydration impact COPD airway clearance</article-title><source>Eur Respir J</source><year>2020</year><volume>55</volume><fpage>1900419</fpage><pub-id pub-id-type="pmid">31672759</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_041"><label>41</label><element-citation publication-type="journal"><name><surname>Kellerman</surname><given-names>DJ</given-names></name><article-title>P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance</article-title><source>Chest</source><year>2002</year><volume>121</volume><fpage>201S</fpage><comment>&#x02013;</comment><lpage>5S</lpage><pub-id pub-id-type="pmid">12010852</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_042"><label>42</label><element-citation publication-type="journal"><name><surname>McCormack</surname><given-names>P</given-names></name><name><surname>Burnham</surname><given-names>P</given-names></name><name><surname>Southern</surname><given-names>KW</given-names></name><article-title>Autogenic drainage for airway clearance in cystic fibrosis</article-title><source>Cochrane Database Syst Rev</source><year>2017</year><volume>10</volume><fpage>CD009595</fpage><pub-id pub-id-type="pmid">28984368</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_043"><label>43</label><element-citation publication-type="journal"><name><surname>Osman</surname><given-names>LP</given-names></name><name><surname>Roughton</surname><given-names>M</given-names></name><name><surname>Hodson</surname><given-names>ME</given-names></name><name><surname>Pryor</surname><given-names>JA</given-names></name><article-title>Short-term comparative study of high frequency chest wall oscillation and European airway clearance techniques in patients with cystic fibrosis</article-title><source>Thorax</source><year>2010</year><volume>65</volume><fpage>196</fpage><comment>&#x02013;</comment><lpage>200</lpage><pub-id pub-id-type="pmid">19703826</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0094_ref_044"><label>44</label><element-citation publication-type="journal"><name><surname>Mineshita</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Miyazawa</surname><given-names>T</given-names></name><article-title>[Bronchoscopic treatments for COPD]</article-title><source>Nihon Rinsho</source><year>2016</year><volume>74</volume><fpage>807</fpage><comment>&#x02013;</comment><lpage>12</lpage><pub-id pub-id-type="pmid">27254951</pub-id>
</element-citation></ref></ref-list></back></article>
